Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against ...

SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage ...

SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs ...

SAN JOSE, Calif. - Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company with a market capitalization of $21.47 million, has announced a research collaboration ...

Rani Therapeutics (NASDAQ:RANI – Free Report) had its price target trimmed by Oppenheimer from $14.00 to $4.00 in a research note released on Friday,Benzinga reports.The brokerage currently has ...

Rani Therapeutics Holdings, Inc. has announced a research agreement with Chugai Pharmaceutical Co., Ltd. to evaluate the potential of Rani’s oral delivery technology, specifically the RaniPill ...

May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics ...

In a recent 8-K filing with the Securities and Exchange Commission, Rani Therapeutics Holdings , Inc., a Delaware-incorporated pharmaceutical company, announced entering into a significant agreement ...

RANI READ THE FULL RANI RESEARCH REPORT On May 13 th Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) reported first quarter 2025 results. Year to date, Rani has updated investors on ProGen’s PG102 ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...